Ultrasensitive assays for detection of orf1p in biofluids
AssigneesThe Brigham and Women's Hospital, Inc., The General Hospital Corporation, Dana-Farber Cancer Institute, Inc., The Rockefeller University, The Johns Hopkins University
InventorsMartin Taylor, Connie Wu, Peter Clayton Fridy, John Paul LaCava, Brian T. Chait, Kelly Rebecca Molloy, Michael Paul Rout, Padric Garden, Limor Cohen, David R. Walt, Kathleen Burns
Life of this patent
Estimating the term…
Abstract
Described herein are methods and compositions for accurate detection of cancer using ultrasensitive immunoassays, e.g., digital ELISA, to detect open reading frame 1 protein (ORF1p), which is encoded by the LINE-1 retrotransposon, in biofluids.
Claims23
A method comprising:
- providing a sample, preferably a sample comprising a biofluid or tissue, preferably wherein the biofluid is blood, serum, or plasma, or the tissue is a tissue lysate, from a subject, and determining a level of ORF1p in the sample with an ultrasensitive protein assay.
A single domain antibody or antigen-binding fragment thereof that binds to human ORF1p, comprising a sequence at least 90% identical to a nanobody sequence or CDR1, CDR2, and CDR3 therefrom as shown in table B.
An antibody or antigen binding portion thereof that specifically binds to human ORF1p, wherein the antibody or antigen binding portion thereof comprises at least one of:
- a heavy chain variable region (VH) comprising or consisting of a VH sequence that is at least 95% identical to a sequence shown in Table D or FIGS. 20A-J, or CDR1, CDR2, and CDR3 therefrom;
- and/or
- a light chain variable region (VL) comprising or consisting of a VL sequence that is at least 95% identical to a sequence shown in Table D or FIGS. 20A-J, or CDR1, CDR2, and CDR3 therefrom, preferably wherein the VH and VL or CDRs are from the same antibody.
Dependencies are inferred from the claim text.